<p>, /PRNewswire/ --</p>
<p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2024 年 11 月 4 日至 2025 年 10 月 3 日期间（包括这两个日期）购买 Skye Bioscience, Inc.（纳斯达克代码：SKYE）证券的投资者，注意 2026 年 1 月 16 日的主要原告截止日期。</p>
<p>那么：如果您在该期间购买了 Skye 的证券，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理费用安排获得赔偿。</p>
<p>接下来该做什么：要加入 Skye Bioscience, Inc.的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=48064 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已经提起。如果您希望担任主要原告，必须在 2026 年 1 月 16 日之前向法院提出申请。主要原告是代表其他集体成员在诉讼中行事的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的公司没有相应的经验、资源或任何有意义的同行认可。这些公司中的许多实际上并不进行证券集体诉讼，而只是作为中介，转介客户或与实际进行诉讼的律师事务所合作。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对一家中国公司的最大证券集体诉讼和解。2017 年，罗森律师事务所被 ISS 证券集体诉讼服务评为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据诉讼， defendants 在整个集体诉讼期间做出了关于 Skye 的业务、运营和前景的重大虚假和误导性陈述。具体而言， defendants 做出了虚假和/或误导性陈述，和/或未能披露：(1) nimacimab 的效果不如 defendants 所让投资者相信的那样；(2) 因此，nimacimab 的临床、监管和商业前景被夸大；(3) 因此， defendants 的公开声明在所有相关时间都是重大虚假和误导的。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 Skye Bioscience 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=48064 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择您自己的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任主要原告。</p>
<p>关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约， NY 10016</p>
<p>电话：(212) 686-1060</p>
<p>免费电话：(866) 767-3653</p>
<p>传真：(212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE2Jk5ld3NJdGVtSWQ9REM2NTI3NSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTYxNTAxUFJfTkVXU19VU1BSX19fX19EQzY1Mjc1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE2Jk5ld3NJdGVtSWQ9REM2NTI3NSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTYxNTAxUFJfTkVXU19VU1BSX19fX19EQzY1Mjc1"/></p>

SKYE

<p>罗森律师事务所提醒 Skye Bioscience, Inc.（纳斯达克代码：SKYE）的投资者，有机会领导一起证券欺诈诉讼。购买了 2024 年 11 月 4 日至 2025 年 10 月 3 日期间证券的投资者，必须在 2026 年 1 月 16 日之前申请成为主要原告。诉讼声称 Skye 对其产品 nimacimab 做出了虚假陈述，导致投资者损失。感兴趣的各方可以联系该事务所以获取有关加入集体诉讼的更多信息</p>

<p>, /PRNewswire/ --</p>
<div class="lb-trans"><p>, /PRNewswire/ --</p>
</div><p>Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the &#34;Class Period&#34;), of the important January 16, 2026 lead plaintiff deadline.</p>
<div class="lb-trans"><p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2024 年 11 月 4 日至 2025 年 10 月 3 日期间（包括这两个日期）购买 Skye Bioscience, Inc.（纳斯达克代码：SKYE）证券的投资者，注意 2026 年 1 月 16 日的主要原告截止日期。</p>
</div><p>So what: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么：如果您在该期间购买了 Skye 的证券，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理费用安排获得赔偿。</p>
</div><p>What to do next: To join the Skye Bioscience, Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 Skye Bioscience, Inc.的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=48064 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已经提起。如果您希望担任主要原告，必须在 2026 年 1 月 16 日之前向法院提出申请。主要原告是代表其他集体成员在诉讼中行事的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的公司没有相应的经验、资源或任何有意义的同行认可。这些公司中的许多实际上并不进行证券集体诉讼，而只是作为中介，转介客户或与实际进行诉讼的律师事务所合作。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对一家中国公司的最大证券集体诉讼和解。2017 年，罗森律师事务所被 ISS 证券集体诉讼服务评为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements regarding Skye's business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than defendants had led investors to believe; (2) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据诉讼， defendants 在整个集体诉讼期间做出了关于 Skye 的业务、运营和前景的重大虚假和误导性陈述。具体而言， defendants 做出了虚假和/或误导性陈述，和/或未能披露：(1) nimacimab 的效果不如 defendants 所让投资者相信的那样；(2) 因此，nimacimab 的临床、监管和商业前景被夸大；(3) 因此， defendants 的公开声明在所有相关时间都是重大虚假和误导的。当真实细节进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the Skye Bioscience class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Skye Bioscience 的集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=48064 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择您自己的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任主要原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约， NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话：(212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话：(866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真：(212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE2Jk5ld3NJdGVtSWQ9REM2NTI3NSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTYxNTAxUFJfTkVXU19VU1BSX19fX19EQzY1Mjc1" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC65275&amp;Transmission_Id=202601161501PR_NEWS_USPR_____DC65275&amp;DateId=20260116"/></p>

SKYE 最后期限：SKYE 投资者有机会主导 Skye Bioscience, Inc.证券欺诈诉讼